Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01721603 : A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases
PhasePhase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

1. Histologically-confirmed BRAFV600E melanoma

2. Up to 4 untreated brain metastases (at least 1 > 0.5 cm) with no metastasis larger
than 3 cm as assessed by a gadolinium-enhanced MRI of the brain.

3. ECOG PS 0-2

4. 14 days elapsed from last treatment with surgery.

5. At least 28 days or five half-lives (whichever is longer) have elapsed from last dose
of any approved or investigational therapy for metastatic melanoma.

6. Appropriate birth control for men and women with childbearing potential

7. Corticosteroid dose stable for at least 14 days

8. Adequate end-organ function:

- ANC ? 1.5x109/L

- Hemoglobin ? 9 g/dL

- Platelets ?100 x109/L

- Total bilirubin ? 1.5x ULN

- AST and ALT ? 2.5x ULN

- Creatinine ? 1.5 mg/dL

- PT/PTT ? 1.5x ULN

- LVEF ? 50%

9. Age >18 years

Exclusion Criteria:

1. Neurological symptoms from melanoma brain metastases

2. Patients may not have received prior therapy with dabrafenib, vemurafenib, or other
potent, highly effective BRAF inhibitors. Prior therapy with sorafenib is permitted.

3. Any indication for urgent or emergent neurosurgery. Patient may enroll after
neurosurgery at least 14 days after neurosurgery as long as they meet all other study
qualifications.

4. Any prior radiation therapy to the brain including stereotactic radiosurgery or whole
brain irradiation.

5. Pregnant or lactating women. The effects of dabrafenib on the developing human fetus
are unknown. For this reason, women of child-bearing potential and men must agree to
use a highly effective method of contraception including: hormonal contraceptives
(oral contraceptives, Nuvaring, Depo Provera) an intrauterine device, true abstinence
or two barrier methods of birth control including condoms with cervical cap or
diaphragm. Baseline pregnancy testing is required for all women of child-bearing
potential. Should a woman become pregnant or suspect she is pregnant while she or
her partner is participating in this study, she should inform her treating physician
immediately. Men treated or enrolled on this protocol who are sexually active with
women of child bearing potential must also agree to use adequate contraception prior
to and during the study as outlined above, and for, and four months after completion
of study drug administration.

6. History of known cardiac arrhythmias or acute coronary syndromes within the past 24
weeks.

7. History of a second malignancy with evidence of active disease within the past 3
years except non-melanoma skin cancer, indolent prostate cancer, and stable CLL
without lymphadenopathy

8. Complete resection of a single brain metastasis or of all known brain metastases.
Patients who have undergone subtotal resection are eligible providing residual
disease is < 2.0 cm in maximum diameter.

9. Patients with metastases within 2 mm of the optic nerve or optic chiasm so that some
portion of the optic nerve or chiasm would receive > 9 Gy from radiosurgery.

10. Patients with metastases in the brainstem.

11. Contraindication to MRI (such as cardiac pacemaker).

12. The following medications or non-drug therapies are prohibited:

- Other anti-cancer therapy while on treatment in this study.

- Use of other investigational drugs within 28 days preceding the first dose of
dabrafenib.

- Antiretroviral drugs. Subjects with known HIV are ineligible for study
participation.

- Herbal remedies (i.e., St. John's wort).

- Drugs that are strong inhibitors or inducers of CYP3A or CYP2C8, p-glycoprotein
(Pgp) or Bcrp transporter because they may alter dabrafenib concentrations. The
list may be modified based on emerging data. These include but are not limited
to those listed in Appendix 2; consider therapeutic substitutions for these
medications.

13. Unresolved toxicity of National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.0. Grade 2 or higher from previous anti-cancer therapy,
except alopecia.

14. Presence of active gastrointestinal disease or other condition that will interfere
significantly with the absorption of drugs. If clarification is needed as to whether
a condition will significantly affect absorption of drugs, contact the GSK medical
monitor for permission to enroll the subject. PI has final decision regarding which
subjects will be enrolled.

15. A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or
Hepatitis C Virus (HCV) infection. Subjects with laboratory evidence of HBV
clearance may be enrolled with permission of the GSK medical monitor.

16. A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency.

17. Corrected QT (QTc) interval ?480 msecs; history of acute coronary syndromes
(including unstable angina), coronary angioplasty, or stenting within the past 24
weeks; Class II, III, or IV heart failure as defined by the New York Heart
Association (NYHA) functional classification system; abnormal cardiac valve
morphology documented by echocardiogram (subjects with minimal abnormalities
including mild regurgitation/stenosis can be entered on study with approval from the
GSK medical monitor); or history of known cardiac arrhythmias.

18. Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc),
psychological, familial, sociological, or geographical conditions that do not permit
compliance with the protocol; or unwillingness or inability to follow the procedures
required in the protocol.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01721603      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740